Overview

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Phase:
Phase 3
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Treatments:
Conivaptan